Navigation Links
BioMarin to Present at the UBS Global Life Sciences Conference
Date:9/13/2011

NOVATO, Calif., Sept. 13, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 12:30 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
2. BioMarin to Present at the Baird Health Care Conference
3. BioMarin to Present at the Wedbush Life Sciences Conference
4. BioMarin Announces Second Quarter 2011 Financial Results
5. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
6. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
7. BioMarin to Present at the William Blair Growth Stock Conference
8. BioMarin to Present at the Jefferies Global Healthcare Conference
9. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
10. BioMarin Announces First Quarter 2011 Financial Results
11. BioMarin to Present at the Deutsche Bank Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global fluoropolymer market in the healthcare industry ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, ... from industry experts. The report covers the market landscape and its ...
(Date:1/17/2017)... --  Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today ... and pharmaceutical development at Tocagen, will present at Phacilitate Cell ... in Miami . Details of ... ... viruses - what to do when and why Date and Time: ...
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), ... report to their offering. ... The global active pharmaceutical ingredients market is expected to ... 2016, growing at a CAGR of 6.3% from 2016 to 2021. ...
Breaking Medicine Technology:
(Date:1/17/2017)... Chicago, Illinois (PRWEB) , ... January 17, 2017 , ... ... Antonio Breast Cancer Symposium (SABCS) or those who desire a more intimate review and ... Antonio: Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Healthful-Flex. , The company, owned and operated by Ed Stroup, was created ... reasonable price with the highest level of customer service. Healthful Balance products can ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Mirror Mirror ... earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, ... part of this elite group of providers. , Produced by Zeltiq, CoolSculpting is ...
Breaking Medicine News(10 mins):